▼ -3.03% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for BioAtla in the last 3 months. The average price target is $48.00, with a high forecast of $51.00 and a low forecast of $45.00. The average price target represents a -3.03% upside from the last price of $49.50.
The current consensus among 4 contributing investment analysts is to buy stock in BioAtla.
BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.